trending Market Intelligence /marketintelligence/en/news-insights/trending/VfMSuqkiSdAN9QR5923U-w2 content esgSubNav
In This List

Capricor halts Duchenne drug trial after patient suffers allergic reaction

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Capricor halts Duchenne drug trial after patient suffers allergic reaction

California-based drugmaker Capricor Therapeutics Inc. voluntarily halted testing of its Duchenne muscular dystrophy treatment after a patient had a severe allergic reaction during the trial.

Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness that could lead to death.

Capricor said the patient responded well to medical treatment and is now showing no symptoms.

The trial, dubbed Hope-2, was evaluating Capricor's experimental drug CAP-1002 in young men and boys. The treatment received the U.S. Food and Drug Administration's regenerative medicine advanced therapy designation in February and has also received the FDA's orphan drug and rare pediatric disease designations in the past.

Capricor notified the FDA of the issue and is working with the regulator on a mitigation plan.